Literature DB >> 2124213

Pharmacokinetics of quinolones in renal insufficiency.

J P Fillastre1, A Leroy, B Moulin, M Dhib, F Borsa-Lebas, G Humbert.   

Abstract

The pharmacokinetics of the new fluoroquinolone derivatives have been extensively studied in patients with various degrees of chronic renal insufficiency during the last few years. Their kinetic profiles depend on the elimination pathways and on the degree of metabolic transformation. Renal insufficiency does not significantly modify pefloxacin kinetics. For the other new quinolones, a decrease in glomerular filtration rate below 20-30 ml/min induces an increase in terminal half-life and a decrease in plasma and renal clearance, related to the degree of renal impairment. These drugs are poorly removed by haemodialysis. Dosage adjustments are required, particularly in severe renal failure and for the drugs almost exclusively excreted, in unchanged form, via the renal route.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2124213     DOI: 10.1093/jac/26.suppl_b.51

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  11 in total

Review 1.  Ofloxacin. A reappraisal of its antimicrobial activity, pharmacology and therapeutic use.

Authors:  P A Todd; D Faulds
Journal:  Drugs       Date:  1991-11       Impact factor: 9.546

Review 2.  Principles of drug administration in renal insufficiency.

Authors:  Y W Lam; S Banerji; C Hatfield; R L Talbert
Journal:  Clin Pharmacokinet       Date:  1997-01       Impact factor: 6.447

Review 3.  Drug dosage in patients during continuous renal replacement therapy. Pharmacokinetic and therapeutic considerations.

Authors:  P Reetze-Bonorden; J Böhler; E Keller
Journal:  Clin Pharmacokinet       Date:  1993-05       Impact factor: 6.447

Review 4.  Enoxacin: a reappraisal of its clinical efficacy in the treatment of genitourinary tract infections.

Authors:  S S Patel; C M Spencer
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

5.  Single-dose pharmacokinetics of oral fleroxacin in bacteremic patients.

Authors:  J Schrenzel; F Cerruti; M Herrmann; T Leemann; E Weidekamm; R Portmann; B Hirschel; D P Lew
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

6.  Pharmacokinetics of fleroxacin after multiple oral dosing in patients receiving regular hemodialysis.

Authors:  D E Uehlinger; F Schaedeli; M Kinzig; F Sörgel; F J Frey
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

7.  Altered pharmacokinetics of enrofloxacin in experimental models of hepatic and renal impairment.

Authors:  Y H Hwang; M S Kim; I B Song; J H Lim; B K Park; H I Yun
Journal:  Vet Res Commun       Date:  2008-12-16       Impact factor: 2.459

Review 8.  The quinolones. An overview of their pharmacology.

Authors:  A Fitton
Journal:  Clin Pharmacokinet       Date:  1992       Impact factor: 6.447

Review 9.  Epidemiology, definition and treatment of complicated urinary tract infections.

Authors:  Florian M E Wagenlehner; Truls E Bjerklund Johansen; Tommaso Cai; Bela Koves; Jennifer Kranz; Adrian Pilatz; Zafer Tandogdu
Journal:  Nat Rev Urol       Date:  2020-08-25       Impact factor: 14.432

10.  Effects of berberine and hwangryunhaedok-tang on oral bioavailability and pharmacokinetics of ciprofloxacin in rats.

Authors:  Youn-Hwan Hwang; Won-Kyung Cho; Doorye Jang; Jeong-Ho Ha; Kiyoun Jung; Hyo-In Yun; Jin Yeul Ma
Journal:  Evid Based Complement Alternat Med       Date:  2012-10-24       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.